|
Grand Pharmaceutical Group Limited is an investment holding company operating in the pharmaceutical and biotechnology sectors. The company focuses on nuclear medicine for oncology and cardiovascular interventions, pharmaceutical technology, and biotechnology. Its business segments include radiopharmaceuticals, high-end formulations, and health and nutrition products, with a specific emphasis on amino acids. Key products and brands include the Y-90 resin microspheres, the Lai Te Ling (Olopatadine Mometasone) nasal spray, and the TP-03 treatment for Demodex blepharitis. The company maintains a partnership with Telix for radiopharmaceutical development, specifically for RDC products such as TLX101 and TLX591-CDx. It serves markets in China and is pursuing international expansion into North America and the European Union. The company's history dates back to 1939. Summarised from the company's own disclosures, fiscal year ended Apr 2026 |
Industry Drug Manufacturers - General | Homepage grandpharm.com |
| Sector Healthcare | IR page grandpharm.com | |
|
Tags
nuclear medicine, radiopharmaceuticals, oncology, cardiovascular interventions, amino acids, health and nutrition, pharmaceutical technology, biotechnology, Telix, TLX101, TLX591-CDx, TLX250-CDx, Lai Te Ling, TP-03, Y-90 resin microspheres, Chengdu Pu'er Weiye Medical Technology Co. Ltd., Hebei Grand Jiufu
|
Press page grandpharm.com/news |
Metrics
| Valuation | |
|---|---|
| Market cap | HK$ 14.78B |
| Market cap (USD) | $ 1.884B |
| P/E | 11.75 |
| PEG | — |
| P/BV | 0.84 |
| P/S | 1.18 |
| P/OCF | 8.62 |
| P/FCF | — |
| Dividend yield | 4.1% |
| Turnover / mcap | 0.05% |
| Returns | |
|---|---|
| ROE | 7.4% |
| ROI | 6.2% |
| ROIC | 6.2% |
| Profit margin | 10.1% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | -15.8% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | 28.8% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | 41.2% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.283B | 11.645B | 10.53B | 9.562B | 8.598B | 6.353B | 6.591B | 5.958B | 4.771B | 3.696B | 3.246B | 3.122B | 2.658B | 2.059B | 1.648B | 1.055B |
| Net profit | 1.241B | 2.468B | 1.88B | 2.079B | 2.403B | 1.793B | 1.151B | 712.667M | 460.811M | 269.143M | 180.906M | 175.208M | 99.658M | 67.305M | 54.235M | 97.973M |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpAnnouncements and reports published on HKEXnews, newest first, monthly and next-day returns, proxy forms and board-meeting notices included. The link opens the announcement on HKEXnews. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Grand Pharmaceutical Group Limited
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVEE | 0.06% | 141,500 | $ 77.989K | Nov 16, 2026 |
| AVES | 0.02% | 614,000 | $ 338.41K | Nov 16, 2026 |
| AVSE | 0.02% | 70,000 | $ 38.581K | Nov 16, 2026 |
| DFEV | 0.02% | 747,500 | $ 413.073K | Nov 12, 2026 |
| AVEM | 0.01% | 6,919,500 | $ 3.814M | Nov 16, 2026 |
| DFEM | 0.01% | 1,526,000 | $ 843.277K | Nov 12, 2026 |
| DFAE | 0.01% | 1,308,000 | $ 722.809K | Nov 12, 2026 |
| DFAX | 0.00% | 813,500 | $ 449.545K | Nov 12, 2026 |






